Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic…
PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse ™ Vybrance ™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed
How this was made
The 30-second read
Why it matters
The enrollment completion reduces execution risk for the PRECISE-BTN study, setting the stage for data that could drive valuation.
Market read
Milestone may attract interest from investors focused on innovative medical‑device biotech, but price impact will hinge on forthcoming efficacy data.
What to watch
Potential competition from other minimally invasive thyroid‑nodule treatments and reimbursement uncertainties.
Background
Pulse Biosciences develops nanosecond pulsed field ablation (nsPFA) technology for soft‑tissue ablation, expanding beyond thyroid applications.
Ticker impact
Pulse Biosciences announced completion of enrollment (100 patients) in its PRECISE-BTN clinical study for the nPulse Vybrance system.
Potential modest upside as investors price in a clearer path to data read‑out and possible regulatory filing.
Enrollment completion is a concrete step forward, but no efficacy data are yet released; market reaction will depend on upcoming results.
Market effects
Strengthens the emerging nanosecond PFA therapeutic sector and may boost peer biotech valuations.
Limited to U.S. biotech investors; no broader regional effect.
Minor global impact; primarily relevant to niche medical‑device and biotech markets.
Counterpoint
Without efficacy data, the enrollment milestone could be over‑hyped; investors may wait for results before committing.
Key entities
- CompanyPulse Biosciences, Inc.
Developer of nPulse technology and the Vybrance percutaneous electrode system.
- IndividualRalph P. Tufano, MD
Principal investigator overseeing the first patient follow‑up.
